Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.
Cell-of-origin
Hans algorithm
Leg type
Lymph2Cx algorithm
Primary cutaneous diffuse large B-cell lymphoma
Primary cutaneous follicle center lymphoma
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
24
08
2021
accepted:
28
12
2021
revised:
15
12
2021
pubmed:
15
1
2022
medline:
12
4
2022
entrez:
14
1
2022
Statut:
ppublish
Résumé
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary cutaneous follicle center lymphoma with a diffuse population of large cells (PCFCL-LC) are both primary cutaneous B-cell lymphomas with large-cell morphology (CLBCL) but with different clinical characteristics and behavior. In systemic diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), gene-expression profiling (GEP) revealed two molecular subgroups based on their cell-of-origin (COO) with prognostic significance: the germinal center B-cell-like (GCB) subtype and the activated B-cell-like (ABC) subtype. This study investigated whether COO classification is a useful tool for classification of CLBCL. For this retrospective study, 51 patients with PCDLBCL-LT and 15 patients with PCFCL-LC were analyzed for their COO according to the immunohistochemistry-based Hans algorithm and the NanoString GEP-based Lymph2Cx algorithm. In PCFCL-LC, all cases (100%) classified as GCB by both Hans and Lymph2Cx. In contrast, COO classification in PCDLBCL-LT was heterogeneous. Using Hans, 75% of the PCDLBCL-LT patients classified as non-GCB and 25% as GCB, while Lymph2Cx classified only 18% as ABC, 43% as unclassified/intermediate, and 39% as GCB. These COO subgroups did not differ in the expression of BCL2 and IgM, mutations in MYD88 and/or CD79B, loss of CDKN2A, or survival. In conclusion, PCFCL-LC uniformly classified as GCB, while PCDLBCL-LT classified along the COO spectrum of DLBCL-NOS using the Hans and Lymph2Cx algorithms. In contrast to DLBCL-NOS, the clinical relevance of COO classification in CLBCL using these algorithms has limitations and cannot be used as an alternative for the current multiparameter approach in differentiation of PCDLBCL-LT and PCFCL-LC.
Identifiants
pubmed: 35028710
doi: 10.1007/s00428-021-03265-5
pii: 10.1007/s00428-021-03265-5
pmc: PMC8990933
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
667-675Informations de copyright
© 2022. The Author(s).
Références
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES (2019) The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas Blood. https://doi.org/10.1182/blood-2018-11-881268
Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, Canninga-van Dijk MR, Geerts ML, Hebeda KM, Kluin PM, Lam KH, Meijer CJ, Willemze R (2007) Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 25:1581–1587. https://doi.org/10.1200/JCO.2006.09.6396
doi: 10.1200/JCO.2006.09.6396
pubmed: 17353548
Willemze R, Meijer CJ, Scheffer E, Kluin PM, Van Vloten WA, Toonstra J, Van der Putte SC (1987) Diffuse large cell lymphomas of follicular center cell origin presenting in the skin. A clinicopathologic and immunologic study of 16 patients. Am J Pathol 126:325–333
pubmed: 3548403
pmcid: 1899577
Vermeer MH, Geelen FA, van Haselen CW, van Voorst Vader PC, Geerts ML, van Vloten WA, Willemze R (1996) Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group Arch Dermatol 132:1304–1308
Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Perez JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJ (1997) EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354–371
pubmed: 9207472
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785. https://doi.org/10.1182/blood-2004-09-3502
doi: 10.1182/blood-2004-09-3502
pubmed: 15692063
Koens L, Vermeer MH, Willemze R, Jansen PM (2010) IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. Am J Surg Pathol 34:1043–1048. https://doi.org/10.1097/PAS.0b013e3181e5060a
doi: 10.1097/PAS.0b013e3181e5060a
pubmed: 20551823
Koens L, Zoutman WH, Ngarmlertsirichai P, Przybylski GK, Grabarczyk P, Vermeer MH, Willemze R, Jansen PM, Schmidt CA, Tensen CP (2014) Nuclear factor-kappaB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol 134:290–292. https://doi.org/10.1038/jid.2013.265
doi: 10.1038/jid.2013.265
pubmed: 23863863
Menguy S, Gros A, Pham-Ledard A, Battistella M, Ortonne N, Comoz F, Balme B, Szablewski V, Lamant L, Carlotti A, Lorton MH, de Muret A, Le Gall F, Franck F, Croue A, Cappellen D, Beylot-Barry M, Merlio JP, Vergier B (2016) MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B-Cell lymphoma. J Invest Dermatol 136:1741–1744. https://doi.org/10.1016/j.jid.2016.04.018
doi: 10.1016/j.jid.2016.04.018
pubmed: 27189828
Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP (2012) MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 132:2118–2120. https://doi.org/10.1038/jid.2012.102
doi: 10.1038/jid.2012.102
pubmed: 22495176
Senff NJ, Zoutman WH, Vermeer MH, Assaf C, Berti E, Cerroni L, Espinet B, de Misa Cabrera RF, Geerts ML, Kempf W, Mitchell TJ, Paulli M, Petrella T, Pimpinelli N, Santucci M, Whittaker SJ, Willemze R, Tensen CP (2009) Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 129:1149–1155. https://doi.org/10.1038/jid.2008.357
doi: 10.1038/jid.2008.357
pubmed: 19020554
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511. https://doi.org/10.1038/35000501
doi: 10.1038/35000501
pubmed: 10676951
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. https://doi.org/10.1182/blood-2003-05-1545
doi: 10.1182/blood-2003-05-1545
pubmed: 14504078
Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD (2015) Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 33:2848–2856. https://doi.org/10.1200/JCO.2014.60.2383
doi: 10.1200/JCO.2014.60.2383
pubmed: 26240231
pmcid: 4554747
Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214–1217. https://doi.org/10.1182/blood-2013-11-536433
doi: 10.1182/blood-2013-11-536433
pubmed: 24398326
pmcid: 3931191
Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, Willemze R, Tensen CP, Vermeer MH (2005) Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105:3671–3678. https://doi.org/10.1182/blood-2004-04-1594
doi: 10.1182/blood-2004-04-1594
pubmed: 15308563
Schrader AMR, Jansen PM, Vermeer MH, Kleiverda JK, Vermaat JSP, Willemze R (2018) High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large B-cell lymphoma, leg type. Am J Surg Pathol 42:1488–1494. https://doi.org/10.1097/PAS.0000000000001132
doi: 10.1097/PAS.0000000000001132
pubmed: 30113335
Swerdlow SH (ed) (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, Pages
van Eijk R, Stevens L, Morreau H, van Wezel T (2013) Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis. Exp Mol Pathol 94:121–125. https://doi.org/10.1016/j.yexmp.2012.06.004
doi: 10.1016/j.yexmp.2012.06.004
pubmed: 22750048
de Groen RAL, van Eijk R, Bohringer S, van Wezel T, Raghoo R, Ruano D, Jansen PM, Briaire-de Bruijn I, de Groot FA, Kleiverda K, Te Boome L, Terpstra V, Levenga H, Nicolae A, Posthuma EFM, Focke-Snieders I, Hardi L, den Hartog WCE, Bohmer LH, Hogendoorn PCW, van den Berg A, Diepstra A, Nijland M, Lugtenburg PJ, Kersten MJ, Pals ST, Veelken H, Bovee J, Cleven AHG, Vermaat JSP (2021) Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype Blood Adv 5:3760–3775. https://doi.org/10.1182/bloodadvances.2021005215
Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343–346
doi: 10.1016/0197-2456(96)00075-X
pubmed: 8889347
Menguy S, Beylot-Barry M, Marie P, Pham Ledard A, Frison E, Comoz F, Battistella M, Szablewski V, Balme B, Croue A, Franck F, Ortonne N, Tournier E, Lamant L, Carlotti A, De Muret A, Le Gall F, Lorton MH, Merlio JP, Vergier B (2019) Primary cutaneous large B-cell lymphomas: relevance of the 2017 WHO classification histopathology. https://doi.org/10.1111/his.13832
Oschlies I, Kohler CW, Szczepanowski M, Koch K, Gontarewicz A, Metze D, Hillen U, Richter J, Spang R, Klapper W (2017) Spindle-cell variants of primary cutaneous follicle center B-cell lymphomas are germinal center B-cell lymphomas by gene expression profiling using a formalin-fixed paraffin-embedded specimen. J Invest Dermatol 137:2450–2453. https://doi.org/10.1016/j.jid.2017.06.016
doi: 10.1016/j.jid.2017.06.016
pubmed: 28684330
Felcht M, Klemke CD, Nicolay JP, Weiss C, Assaf C, Wobser M, Schlaak M, Hillen U, Moritz R, Tantcheva-Poor I, Nashan D, Beyer M, Dippel E, Muller CSL, Sachse MM, Meiss F, Geraud C, Marx A, Goerdt S, Geissinger E, Kempf W (2019) Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: clinical, morphologic and prognostic differences J Dtsch Dermatol Ges. https://doi.org/10.1111/ddg.13773
Elder DE (ed) (2018) WHO classification of skin tumours. IARC, Lyon, Pages
Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ, Spaargaren M, Pals ST (2013) High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 3:e139. https://doi.org/10.1038/bcj.2013.28
doi: 10.1038/bcj.2013.28
pubmed: 24013661
pmcid: 3789201
Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ, Spaargaren M, Pals ST (2014) High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma Leukemia 28:719–720. https://doi.org/10.1038/leu.2013.348
Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP (2018) High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood 131:2086–2089. https://doi.org/10.1182/blood-2017-12-822817
doi: 10.1182/blood-2017-12-822817
pubmed: 29514783
Lucioni M, Pescia C, Bonometti A, Fraticelli S, Moltrasio C, Ramponi A, Riboni R, Roccio S, Ferrario G, Arcaini L, Goteri G, Berti E, Paulli M (2021) Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes. Hum Pathol 111:1–9. https://doi.org/10.1016/j.humpath.2021.01.006
doi: 10.1016/j.humpath.2021.01.006
pubmed: 33548250
Pasqualucci L (2019) Molecular pathogenesis of germinal center-derived B cell lymphomas. Immunol Rev 288:240–261. https://doi.org/10.1111/imr.12745
doi: 10.1111/imr.12745
pubmed: 30874347
Bodor C, Alpar D, Marosvari D, Galik B, Rajnai H, Batai B, Nagy A, Kajtar B, Burjan A, Deak B, Schneider T, Alizadeh H, Matolcsy A, Brandner S, Storhoff J, Chen N, Liu M, Ghali N, Csala I, Bago AG, Gyenesei A, Reiniger L (2020) Molecular subtypes and genomic profile of primary central nervous system lymphoma. J Neuropathol Exp Neurol 79:176–183. https://doi.org/10.1093/jnen/nlz125
doi: 10.1093/jnen/nlz125
pubmed: 31886867
Cheah CY, Wirth A, Seymour JF (2014) Primary testicular lymphoma Blood 123:486-493. https://doi.org/10.1182/blood-2013-10-530659
Twa DDW, Mottok A, Savage KJ, Steidl C (2018) The pathobiology of primary testicular diffuse large B-cell lymphoma: implications for novel therapies. Blood Rev 32:249–255. https://doi.org/10.1016/j.blre.2017.12.001
doi: 10.1016/j.blre.2017.12.001
pubmed: 29289361
Villa D, Tan KL, Steidl C, Ben-Neriah S, Al Moosawi M, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Scott DW, Gascoyne RD, Slack GW (2019) Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Adv 3:3953–3961. https://doi.org/10.1182/bloodadvances.2019000989
doi: 10.1182/bloodadvances.2019000989
pubmed: 31805190
pmcid: 6963243
Montesinos-Rongen M, Brunn A, Bentink S, Basso K, Lim WK, Klapper W, Schaller C, Reifenberger G, Rubenstein J, Wiestler OD, Spang R, Dalla-Favera R, Siebert R, Deckert M (2008) Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 22:400–405. https://doi.org/10.1038/sj.leu.2405019
doi: 10.1038/sj.leu.2405019
pubmed: 17989719
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100:9991–9996. https://doi.org/10.1073/pnas.1732008100
doi: 10.1073/pnas.1732008100
pubmed: 12900505
pmcid: 187912
Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716–3723. https://doi.org/10.1182/blood-2005-03-0897
doi: 10.1182/blood-2005-03-0897
pubmed: 16418334
pmcid: 1895776
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trumper L, Getz G, Shipp MA (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679–690. https://doi.org/10.1038/s41591-018-0016-8
doi: 10.1038/s41591-018-0016-8
pubmed: 29713087
pmcid: 6613387
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, TayKuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396–1407. https://doi.org/10.1056/NEJMoa1801445
doi: 10.1056/NEJMoa1801445
pubmed: 29641966
pmcid: 6010183
Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, Kurtz DM, Liu CL, Khameneh F, Advani RH, Natkunam Y, Myklebust JH, Diehn M, Gentles AJ, Newman AM, Alizadeh AA (2021) The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell 39(1422–1437):e1410. https://doi.org/10.1016/j.ccell.2021.08.011
doi: 10.1016/j.ccell.2021.08.011